用于表皮生长因子受体（EGFR）突变型非小细胞肺癌的一线EGFR激酶抑制剂：而胜出者是…… - Suppr

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

作者信息

Juan O, Yousaf N, Popat S

机构信息

Department of Medical Oncology, University Hospital La Fe, Valencia, Spain; Lung Unit, Royal Marsden Hospital, London, UK.

Lung Unit, Royal Marsden Hospital, London, UK.

出版信息

Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e1-e4. doi: 10.1016/j.clon.2016.09.007. Epub 2016 Sep 27.

DOI:10.1016/j.clon.2016.09.007

PMID:27686969

Abstract

摘要

相似文献

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….用于表皮生长因子受体（EGFR）突变型非小细胞肺癌的一线EGFR激酶抑制剂：而胜出者是……

Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e1-e4. doi: 10.1016/j.clon.2016.09.007. Epub 2016 Sep 27.

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.临床参数和全身炎症状态对表皮生长因子受体突变的非小细胞肺癌患者再次使用表皮生长因子受体酪氨酸激酶抑制剂的影响。

BMC Cancer. 2016 Nov 8;16(1):868. doi: 10.1186/s12885-016-2917-6.

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.作为一线表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型非小细胞肺癌患者预后因素的淋巴细胞与单核细胞比值的基线和趋势

PLoS One. 2015 Aug 27;10(8):e0136252. doi: 10.1371/journal.pone.0136252. eCollection 2015.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.口服表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌：比较药代动力学和药物相互作用。

Cancer Treat Rev. 2014 Sep;40(8):917-26. doi: 10.1016/j.ctrv.2014.06.010. Epub 2014 Jul 1.

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.顺铂暴露后表皮生长因子受体突变型非小细胞肺癌对厄洛替尼敏感性降低：二线厄洛替尼治疗的细胞培养模型

Clin Cancer Res. 2008 Nov 1;14(21):6867-76. doi: 10.1158/1078-0432.CCR-08-0093.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.

Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.表皮生长因子受体酪氨酸激酶抑制剂单独治疗表皮生长因子受体突变型非小细胞肺癌伴脑转移的效果。

Thorac Cancer. 2016 Nov;7(6):648-654. doi: 10.1111/1759-7714.12379. Epub 2016 Sep 1.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.使用一线第一代表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型非小细胞肺癌患者中抗酸剂的使用与新发脑转移

PLoS One. 2016 Feb 19;11(2):e0149722. doi: 10.1371/journal.pone.0149722. eCollection 2016.

引用本文的文献

Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association.非小细胞癌中的预测性生物标志物及其临床病理关联。

South Asian J Cancer. 2019 Oct-Dec;8(4):250-254. doi: 10.4103/sajc.sajc_373_18.

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.奥希替尼和那扎替尼对表达临床相关表皮生长因子受体突变的细胞的疗效特征分析。

Oncotarget. 2017 Nov 6;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 1.

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.表皮生长因子受体（EGFR）激酶抑制剂与非小细胞肺癌（NSCLC）——促进靶向治疗的分子诊断技术进展

Pathol Oncol Res. 2018 Oct;24(4):723-731. doi: 10.1007/s12253-017-0377-1. Epub 2017 Dec 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献